To investigate whether SREBP1 and SREBP2 involved in SOAT1-mediated lymphangiogenesis and VEGFC production, we pharmacologically inhibited SREBP1 and SREBP2 by fatostatin, which displays antitumor activity in cancers by downregulating SREBP- mediated metabolic pathways (Li et al., 2014). This evidence concerns the gene SREBF1 and cancer.